Pretreatment Lymphocyte-to-Monocyte Ratios Predict AIDS-related Diffuse Large B-Cell Lymphoma Overall Survival

Lymphoma
06/11/2020

J Med Virol. 2020 Nov 6. doi: 10.1002/jmv.26655. Online ahead of print.

ABSTRACT

INTRODUCTION: The lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been reported to be useful for predicting the prognosis of various malignancies, including diffuse large B-cell lymphoma (DLBCL). However, little is known about the role of LMR and PLR in the prognosis of DLBCL patients with human immunodeficiency virus (HIV) infection.


METHODS: We retrospectively evaluated the prognostic value of the LMR and PLR in patients with newly diagnosed AIDS-related diffuse large B-cell lymphoma (AR-DLBCL) who were treated with CHOP-like chemotherapy at a single institution.

RESULTS: In 33 AR-DLBCL patients, the median follow up period was 32 months (range: 7-85 months), with an estimated two-year overall survival (OS) rate of 79.9%. The univariate analysis confirmed the LMR ≤2.74 (p = 0.015), PLR ≥337.7 (p = 0.019), and moderate anemia (p = 0.045) were associated with inferior survival. The independent significant association between low LMR and poor OS in the multivariate analysis was identified (HR: 0.033, 95% CI: 0.001-0.853, P=0.040). However, PLR (p = 0.459) and moderate anemia (p = 0.102) did not retain an independent significance in the multivariate analysis. Moreover, compared with the high-LMR group, patients with low-LMR more frequently had B symptoms (P = 0.010) and lower CD4+ T cell count (P < 0.001).

DISCUSSION/CONCLUSION: The pretreatment LMR may be an effective prognostic factor for predicting OS in patients with AR-DLBCL. This article is protected by copyright. All rights reserved.